AIM ImmunoTech Inc. announced a reverse stock split of 1-for-100, effective June 12, 2025, aimed at increasing the share price to comply with NYSE American listing requirements. This decision follows ...
AIM ImmunoTech Inc. Showcases Ampligen Research at U.S.-Poland Science and Technology Symposium 2025
AIM ImmunoTech Inc. announced a presentation on its drug Ampligen at the U.S.-Poland Science and Technology Symposium 2025, held from June 17-20 in Silicon Valley, San Francisco, and Stanford ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results